137 related articles for article (PubMed ID: 29319843)
1. Prediction of Vancomycin Dose for Recommended Trough Concentrations in Pediatric Patients With Cystic Fibrosis.
Amin RW; Guttmann RP; Harris QR; Thomas JW
J Clin Pharmacol; 2018 May; 58(5):662-665. PubMed ID: 29319843
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetics of intermittent vancomycin in children with cystic fibrosis.
Stockmann C; Sherwin CM; Zobell JT; Lubsch L; Young DC; Olson J; Noyes BE; Ampofo K; Spigarelli MG
Pharmacotherapy; 2013 Dec; 33(12):1288-96. PubMed ID: 23824677
[TBL] [Abstract][Full Text] [Related]
3. Impact of a hospitalwide increase in empiric pediatric vancomycin dosing on initial trough concentrations.
Frymoyer A; Guglielmo BJ; Wilson SD; Scarpace SB; Benet LZ; Hersh AL
Pharmacotherapy; 2011 Sep; 31(9):871-6. PubMed ID: 21923588
[TBL] [Abstract][Full Text] [Related]
4. Continuous infusion vancomycin for treatment of methicillin-resistant Staphylococcus aureus in cystic fibrosis patients.
Fung L
Ann Pharmacother; 2012 Oct; 46(10):e26. PubMed ID: 23032658
[TBL] [Abstract][Full Text] [Related]
5. Desired vancomycin trough serum concentration for treating invasive methicillin-resistant Staphylococcal infections.
Frymoyer A; Guglielmo BJ; Hersh AL
Pediatr Infect Dis J; 2013 Oct; 32(10):1077-9. PubMed ID: 23652479
[TBL] [Abstract][Full Text] [Related]
6. Achievement of Therapeutic Vancomycin Trough Serum Concentrations with Empiric Dosing in Neonatal Intensive Care Unit Patients.
Ringenberg T; Robinson C; Meyers R; Degnan L; Shah P; Siu A; Sturgill M
Pediatr Infect Dis J; 2015 Jul; 34(7):742-7. PubMed ID: 25629890
[TBL] [Abstract][Full Text] [Related]
7. Association Between Vancomycin Trough Concentrations and Duration of Methicillin-Resistant Staphylococcus aureus Bacteremia in Children.
Hsu AJ; Hamdy RF; Huang Y; Olson JA; Ghobrial S; Gerber JS; Hersh AL; Tamma PD
J Pediatric Infect Dis Soc; 2018 Dec; 7(4):338-341. PubMed ID: 28992126
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of clinical outcome in children and adolescents receiving vancomycin for invasive infections due to methicillin-resistant Staphylococcus aureus: impact of increasing vancomycin MICs.
Arun A; Swamy S; Jacob K; Sharma R; Kohlhoff SA; Hammerschlag MR
Minerva Pediatr; 2018 Jun; 70(3):207-211. PubMed ID: 28006894
[TBL] [Abstract][Full Text] [Related]
9. Phase I, Dose-Escalating Study of the Safety and Pharmacokinetics of Inhaled Dry-Powder Vancomycin (AeroVanc) in Volunteers and Patients with Cystic Fibrosis: a New Approach to Therapy for Methicillin-Resistant Staphylococcus aureus.
Waterer G; Lord J; Hofmann T; Jouhikainen T
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31964790
[TBL] [Abstract][Full Text] [Related]
10. An Evaluation of Vancomycin Area Under the Curve Estimation Methods for Children Treated for Acute Pulmonary Exacerbations of Cystic Fibrosis Due to Methicillin-Resistant Staphylococcus aureus.
Stockmann C; Olson J; Rashid J; Lubsch L; Young DC; Hersh AL; Frymoyer A; Ampofo K; Liu X; Wang Y; Sherwin CMT; Zobell JT
J Clin Pharmacol; 2019 Feb; 59(2):198-205. PubMed ID: 30371946
[TBL] [Abstract][Full Text] [Related]
11. The relationship between trough concentration of vancomycin and effect on methicillin-resistant Staphylococcus aureus in critically ill patients.
Cheong JY; Makmor-Bakry M; Lau CL; Abdul Rahman R
S Afr Med J; 2012 May; 102(7):616-9. PubMed ID: 22748440
[TBL] [Abstract][Full Text] [Related]
12. Vancomycin pharmacokinetics and predicted dosage requirements in pediatric cancer patients.
Abdel Hadi O; Al Omar S; Nazer LH; Mubarak S; Le J
J Oncol Pharm Pract; 2016 Jun; 22(3):448-53. PubMed ID: 26079639
[TBL] [Abstract][Full Text] [Related]
13. The Impact of AUC-Based Monitoring on Pharmacist-Directed Vancomycin Dose Adjustments in Complicated Methicillin-Resistant
Stoessel AM; Hale CM; Seabury RW; Miller CD; Steele JM
J Pharm Pract; 2019 Aug; 32(4):442-446. PubMed ID: 29554847
[TBL] [Abstract][Full Text] [Related]
14. Vancomycin Dosing Considerations in a Real-World Cohort of Obese and Extremely Obese Patients.
Morrill HJ; Caffrey AR; Noh E; LaPlante KL
Pharmacotherapy; 2015 Sep; 35(9):869-75. PubMed ID: 26343549
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of vancomycin serum trough concentrations and outcomes in meticillin-resistant Staphylococcus aureus bacteraemia.
Arshad S; Shoyinka A; Chen A; Jacobsen G; Zervos M
Int J Antimicrob Agents; 2012 Nov; 40(5):474-5. PubMed ID: 22883416
[No Abstract] [Full Text] [Related]
16. Association of Vancomycin Trough Concentration With Response to Treatment for Acute Pulmonary Exacerbation of Cystic Fibrosis.
Fusco NM; Francisconi R; Meaney CJ; Duman D; Frederick CA; Prescott WA
J Pediatric Infect Dis Soc; 2017 Sep; 6(3):e103-e108. PubMed ID: 28903517
[TBL] [Abstract][Full Text] [Related]
17. The Relationship Between Vancomycin Trough Concentrations and AUC/MIC Ratios in Pediatric Patients: A Qualitative Systematic Review.
Tkachuk S; Collins K; Ensom MHH
Paediatr Drugs; 2018 Apr; 20(2):153-164. PubMed ID: 29344778
[TBL] [Abstract][Full Text] [Related]
18. Association of the clinical efficacy of vancomycin with the novel pharmacokinetic parameter area under the trough level (AUTL) in elderly patients with hospital-acquired pneumonia.
Fukumori S; Tsuji Y; Mizoguchi A; Kasai H; Ishibashi T; Iwamura N; To H
J Clin Pharm Ther; 2016 Aug; 41(4):399-402. PubMed ID: 27144370
[TBL] [Abstract][Full Text] [Related]
19. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia.
Mogle BT; Steele JM; Seabury RW; Dang UJ; Kufel WD
Int J Antimicrob Agents; 2018 Dec; 52(6):805-810. PubMed ID: 30176357
[TBL] [Abstract][Full Text] [Related]
20. Exploration of optimal dosing regimens of vancomycin in patients infected with methicillin-resistant Staphylococcus aureus by modeling and simulation.
Lim HS; Chong YP; Noh YH; Jung JA; Kim YS
J Clin Pharm Ther; 2014 Apr; 39(2):196-203. PubMed ID: 24428720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
